ABCA7 Alzheimer's Gene Disrupts Brain Cell Lipids and Mitochondria
MIT researchers map how ABCA7 loss-of-function variants wreck phosphatidylcholine metabolism and mitochondria in neurons — and find a potential fix.
Summary
Scientists at MIT used single-nucleus RNA sequencing of human post-mortem brain tissue to map how loss-of-function variants in ABCA7 — a strong Alzheimer's risk gene — disrupt cell biology across multiple brain cell types. Excitatory neurons, which express the highest ABCA7 levels, showed the most damage: disrupted lipid metabolism, impaired mitochondrial function, elevated oxidative stress, and reduced synaptic signaling. Experiments in iPSC-derived neurons with ABCA7 variants confirmed these changes and revealed a specific breakdown in phosphatidylcholine synthesis. Remarkably, supplementing these neurons with CDP-choline restored phosphatidylcholine levels, normalized mitochondrial function, reduced amyloid-beta secretion, and reversed neuronal hyperexcitability — pointing to a potential therapeutic strategy for a major genetic subtype of Alzheimer's disease.
Detailed Summary
Alzheimer's disease (AD) is the most common form of dementia, and genetic risk factors beyond APOE4 remain incompletely understood. Loss-of-function (LoF) variants in ABCA7 — a lipid transporter gene — carry an odds ratio of approximately 2 for AD risk, placing them among the strongest known genetic risk factors. Despite this significance, the precise cellular mechanisms by which ABCA7 dysfunction drives AD pathology had remained poorly defined, with most prior studies relying on complete knockouts in mice rather than the specific premature termination codon (PTC) variants found in human patients.
To address this gap, researchers from MIT's Picower Institute performed single-nucleus RNA sequencing (snRNA-seq) on post-mortem prefrontal cortex (BA10) tissue from 12 ABCA7 PTC variant carriers and 24 carefully matched controls drawn from the ROSMAP cohort. Variants studied included splice, frameshift, and nonsense mutations (e.g., p.Trp1245*, p.Leu1403fs, c.4416+2T>G). After rigorous quality control — including genotype-transcriptome matching to rule out sample swaps and batch-effect correction — the final dataset comprised 102,710 high-quality cells across six major neural cell types: excitatory neurons, inhibitory neurons, astrocytes, microglia, oligodendrocytes, and OPCs.
The analysis identified 2,389 genes with nominal evidence of transcriptional perturbation (P < 0.05) across cell types. Excitatory neurons, which expressed the highest ABCA7 levels of any cell type, showed the most pronounced disruptions — upregulation of cellular respiration genes (e.g., NDUFV2) and downregulation of triglyceride biosynthesis (e.g., PPARD), synaptic transmission (e.g., NLGN1, SHISA6), and DNA repair genes. Microglia showed marked downregulation of stress-response genes (e.g., HSPH1), while oligodendrocytes and OPCs showed inflammatory pathway changes (e.g., IL10RB, STAT2). Crucially, the common AD-associated ABCA7 variant p.Ala1527Gly — confirmed by molecular dynamics simulations to structurally alter the ABCA7 protein — produced overlapping transcriptional signatures, suggesting that the mechanism extends beyond rare PTC carriers to a much broader segment of the population.
To experimentally validate these human brain findings, the team generated iPSC-derived neurons carrying ABCA7 PTC variants. These neurons recapitulated the transcriptional disruptions observed in human brain tissue and exhibited measurable functional deficits: impaired mitochondrial respiration, increased oxidative stress markers, and disrupted phosphatidylcholine (PC) metabolism — the lipid substrate most directly linked to ABCA7's known transporter function. These neurons also showed elevated amyloid-beta secretion and neuronal hyperexcitability, both hallmarks of AD pathophysiology.
The most clinically compelling finding was that CDP-choline (citicoline) supplementation — a precursor that boosts phosphatidylcholine synthesis via the Kennedy pathway — reversed these abnormalities. CDP-choline treatment restored PC levels, normalized mitochondrial function, reduced oxidative stress, lowered amyloid-beta secretion, and corrected neuronal hyperexcitability in ABCA7 LoF neurons. This positions CDP-choline, an already FDA-approved and widely available supplement, as a candidate therapeutic intervention for ABCA7-related AD risk. The study provides a mechanistic framework linking ABCA7 dysfunction → phosphatidylcholine depletion → mitochondrial failure → AD-relevant neuronal dysfunction, and opens the door to lipid-targeted therapeutic strategies for a genetically defined AD subgroup.
Key Findings
- snRNA-seq of 102,710 cells from 12 ABCA7 PTC variant carriers and 24 matched controls identified 2,389 genes with nominal transcriptional perturbation (P < 0.05) across six brain cell types
- Excitatory neurons expressed the highest ABCA7 levels of any neural cell type and showed the most extensive transcriptional disruptions, including lipid metabolism, mitochondrial function, DNA repair, and synaptic signaling pathways
- The common AD-associated ABCA7 variant p.Ala1527Gly produced transcriptional signatures overlapping with rare PTC variants, confirmed structurally by molecular dynamics simulations — implicating broader population risk
- iPSC-derived neurons with ABCA7 LoF variants showed measurable impaired mitochondrial respiration, increased oxidative stress, and disrupted phosphatidylcholine (PC) metabolism, directly replicating human brain snRNA-seq findings
- ABCA7 LoF neurons exhibited elevated amyloid-beta secretion and neuronal hyperexcitability — two core AD pathological features directly exacerbated by ABCA7 dysfunction
- CDP-choline supplementation restored phosphatidylcholine synthesis, reversed mitochondrial dysfunction and oxidative stress, and normalized both amyloid-beta secretion and neuronal hyperexcitability in ABCA7 LoF iPSC neurons
- ABCA7 PTC variant carriers showed lower ABCA7 protein levels in the PFC compared to matched non-carriers, confirming haploinsufficiency as the operative mechanism
Methodology
The study combined snRNA-seq of post-mortem human PFC (BA10) tissue from 36 individuals (12 ABCA7 PTC carriers, 24 matched controls) from the ROSMAP cohort with functional experiments in iPSC-derived neurons carrying engineered ABCA7 LoF variants. snRNA-seq was performed on the 10x Genomics Chromium platform, with batch correction, genotype-transcriptome identity validation, and differential expression analyzed via Limma-Voom with covariate adjustment; pathway enrichment used Gene Ontology Biological Process with hypergeometric testing. Molecular dynamics simulations modeled the structural impact of the p.Ala1527Gly variant on ABCA7 protein conformation.
Study Limitations
The human snRNA-seq cohort was relatively small (12 carriers vs. 24 controls), limiting statistical power for rare cell-type-specific findings and requiring cautious interpretation of nominally significant results. The iPSC neuron model, while valuable, may not fully capture the complexity of in vivo human brain cell interactions including glial contributions to neuronal lipid homeostasis. The authors do not explicitly report conflicts of interest in the available text, though the study was conducted at a major academic institution with standard funding disclosures expected in the full paper.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.